Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01739647 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01739647 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 72 participants.
The verdict
NCT01739647, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a single dose study in healthy male and female (of non-child bearing potential) volunteers, to assess the safety, effects on the body, and blood and urine drug levels of AZD3293. AZD3293 is being developed for the treatment of Alzheimer's Disease
Interventions
- DRUG Placebo
- DRUG AZD3293
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01739647
The ClinicalTrials.gov registry entry for NCT01739647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01739647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01739647 about?
NCT01739647 is a clinical study titled "A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects". This is a single dose study in healthy male and female (of non-child bearing potential) volunteers, to assess the safety, effects on the body, and blood and urine drug levels of AZD3293. AZD3293 is being developed for the treatment of Alzheimer's Disease
What is the current status of trial NCT01739647?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2012-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01739647?
The interventions under investigation include: Placebo (DRUG), AZD3293 (DRUG).
Who is sponsoring clinical trial NCT01739647?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.